Evidence map›Paper›PMID 41938083›Full record

ArticleJTO clinical and research reports2026

Brain Metastases in Diffuse Pleural Mesothelioma: Clinical, Histologic, and Molecular Correlates.

Antonio Ocejo, Clare Wilhem, Francis M Bodd, Andrea Arfe, Marjorie G Zauderer, Afsheen Iqbal, Juliana Eng, Yao Yu, Joshua A Budhu, Javin Schefflein and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Antonio OcejoDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Clare WilhemDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Francis M BoddDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrea ArfeDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Marjorie G ZaudererDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Afsheen IqbalDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Juliana EngDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Yao YuDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Joshua A BudhuDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.
Javin ScheffleinDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert YoungDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mark G KrisDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Nelson S MossDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Rabih Bou-NassifDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Charles B SimoneDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Prasad S AdusumilliDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Jennifer L SauterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael OffinDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Introduction: Brain metastases (BrMs) are poorly studied and likely underreported in diffuse pleural mesothelioma (DPM), limiting understanding of risk factors associated with their development. We evaluated the genomic, histologic, and clinical landscapes of patients with DPM and BrMs. Methods: We retrospectively reviewed all patients with a mesothelioma diagnosis treated at the Memorial Sloan Kettering Cancer Center between January 1, 2010, and May 1, 2025, with cross-sectional brain imaging. Clinicopathologic data and treatment outcomes were annotated for patients with BrMs. Results: Among 194 patients with mesothelioma and brain imaging, 16 (8%) had BrMs. Half (n = 8) had tumors of epithelioid histology, 44% (n = 7) biphasic, and 6% (n = 1) sarcomatoid. Compared with our DPM cohort regardless of BrMs (n = 194) or a DPM cohort from The Cancer Genome Atlas (n = 74), patients with DPM and BrMs had a higher prevalence of Conclusions: Our findings suggest that BrM develops relatively late in DPM, is more common than previously reported, and may be enriched in patients with

Indexed as

Brain metastasesDiffuse pleural mesotheliomaGenomicsMesothelioma

Identifiers

PMID41938083
PMCPMC13049206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.